Lene R Madsen1, Lisbeth M Baggesen2, Bjørn Richelsen3, Reimar W Thomsen2. 1. Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N, Denmark. leemas@rm.dk. 2. Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark. 3. Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N, Denmark.
Abstract
AIMS/HYPOTHESIS: The aim of this study was to examine the effect of Roux-en-Y gastric bypass (RYGB) surgery on diabetes remission, subsequent diabetes relapse and micro- and macrovascular complications in individuals with type 2 diabetes and obesity (BMI >35 kg/m2) in a real-world setting. METHODS: This was a population-based cohort study of 1111 individuals with type 2 diabetes treated by RYGB at hospitals in Northern Denmark (2006-2015), and 1074 matched non-operated individuals with type 2 diabetes. Diabetes remission was defined as no glucose-lowering drug use with HbA1c <48 mmol/mol (<6.5%), or metformin monotherapy with HbA1c <42 mmol/mol (<6.0%). Data on complications were ascertained from medical registries with complete follow-up. RESULTS: At 1 year of follow-up, 74% of the cohort treated by RYGB experienced diabetes remission, while 27% had relapsed after 5 years. Predictors of non-remission were age >50 years, diabetes duration >5 years, use of glucose-lowering drugs other than metformin, and baseline HbA1c >53 mmol/mol (>7.0%). Compared with the non-operated cohort using adjusted Cox regression (5.3 years follow-up), the cohort treated by RYGB had 47% lower risk of microvascular complications (HR 0.53 [95% CI 0.38, 0.73]) and a statistically non-significant 24% lower risk of macrovascular complications (HR 0.76 [95% CI 0.49, 1.18]). Diabetes remission vs non-remission at 1 year was associated with reduced HR of 0.43 (95% CI 0.25, 0.72) for microvascular complications and with HR of 0.76 (95% CI 0.40, 1.45) for macrovascular complications. CONCLUSIONS/ INTERPRETATION: In routine clinical care, three out of four individuals with type 2 diabetes and obesity treated by RYGB experienced diabetes remission after 1 year, whereas 27% of these individuals had relapsed at 5 years follow-up. RYGB was associated with substantially decreased risk of microvascular complications and non-significantly fewer macrovascular complications, with early diabetes remission as a clear predictor of reduced microvascular complications.
AIMS/HYPOTHESIS: The aim of this study was to examine the effect of Roux-en-Y gastric bypass (RYGB) surgery on diabetes remission, subsequent diabetes relapse and micro- and macrovascular complications in individuals with type 2 diabetes and obesity (BMI >35 kg/m2) in a real-world setting. METHODS: This was a population-based cohort study of 1111 individuals with type 2 diabetes treated by RYGB at hospitals in Northern Denmark (2006-2015), and 1074 matched non-operated individuals with type 2 diabetes. Diabetes remission was defined as no glucose-lowering drug use with HbA1c <48 mmol/mol (<6.5%), or metformin monotherapy with HbA1c <42 mmol/mol (<6.0%). Data on complications were ascertained from medical registries with complete follow-up. RESULTS: At 1 year of follow-up, 74% of the cohort treated by RYGB experienced diabetes remission, while 27% had relapsed after 5 years. Predictors of non-remission were age >50 years, diabetes duration >5 years, use of glucose-lowering drugs other than metformin, and baseline HbA1c >53 mmol/mol (>7.0%). Compared with the non-operated cohort using adjusted Cox regression (5.3 years follow-up), the cohort treated by RYGB had 47% lower risk of microvascular complications (HR 0.53 [95% CI 0.38, 0.73]) and a statistically non-significant 24% lower risk of macrovascular complications (HR 0.76 [95% CI 0.49, 1.18]). Diabetes remission vs non-remission at 1 year was associated with reduced HR of 0.43 (95% CI 0.25, 0.72) for microvascular complications and with HR of 0.76 (95% CI 0.40, 1.45) for macrovascular complications. CONCLUSIONS/ INTERPRETATION: In routine clinical care, three out of four individuals with type 2 diabetes and obesity treated by RYGB experienced diabetes remission after 1 year, whereas 27% of these individuals had relapsed at 5 years follow-up. RYGB was associated with substantially decreased risk of microvascular complications and non-significantly fewer macrovascular complications, with early diabetes remission as a clear predictor of reduced microvascular complications.
Authors: S M Grundy; I J Benjamin; G L Burke; A Chait; R H Eckel; B V Howard; W Mitch; S C Smith; J R Sowers Journal: Circulation Date: 1999-09-07 Impact factor: 29.690
Authors: Brent L Johnson; Dawn W Blackhurst; Bruce B Latham; David L Cull; Eric S Bour; Thomas L Oliver; Bradley Williams; Spence M Taylor; John D Scott Journal: J Am Coll Surg Date: 2013-02-05 Impact factor: 6.113
Authors: John B Buse; Sonia Caprio; William T Cefalu; Antonio Ceriello; Stefano Del Prato; Silvio E Inzucchi; Sue McLaughlin; Gordon L Phillips; R Paul Robertson; Francesco Rubino; Richard Kahn; M Sue Kirkman Journal: Diabetes Care Date: 2009-11 Impact factor: 19.112
Authors: Geltrude Mingrone; Simona Panunzi; Andrea De Gaetano; Caterina Guidone; Amerigo Iaconelli; Giuseppe Nanni; Marco Castagneto; Stefan Bornstein; Francesco Rubino Journal: Lancet Date: 2015-09-05 Impact factor: 79.321
Authors: Lars Sjöström; Markku Peltonen; Peter Jacobson; Sofie Ahlin; Johanna Andersson-Assarsson; Åsa Anveden; Claude Bouchard; Björn Carlsson; Kristjan Karason; Hans Lönroth; Ingmar Näslund; Elisabeth Sjöström; Magdalena Taube; Hans Wedel; Per-Arne Svensson; Kajsa Sjöholm; Lena M S Carlsson Journal: JAMA Date: 2014-06-11 Impact factor: 56.272
Authors: Sandra K Thygesen; Christian F Christiansen; Steffen Christensen; Timothy L Lash; Henrik T Sørensen Journal: BMC Med Res Methodol Date: 2011-05-28 Impact factor: 4.615
Authors: Sigrun Alba Johannesdottir; Erzsébet Horváth-Puhó; Vera Ehrenstein; Morten Schmidt; Lars Pedersen; Henrik Toft Sørensen Journal: Clin Epidemiol Date: 2012-11-12 Impact factor: 4.790
Authors: Guilherme S Mazzini; Jad Khoraki; Matthew G Browning; Bernardo M Pessoa; Luke G Wolfe; Guilherme M Campos Journal: Obes Surg Date: 2020-03 Impact factor: 4.129
Authors: Isabel Mateo-Gavira; Esteban Sánchez-Toscano; Mª Ángeles Mayo-Ossorio; José Manuel Pacheco-García; Jose Arturo Prada-Oliveira; Francisco Javier Vílchez-López Journal: J Clin Med Date: 2021-05-01 Impact factor: 4.241
Authors: Ana de Hollanda; Albert Lecube; Miguel Angel Rubio; Enric Sánchez; Núria Vilarrasa; José Gregorio Oliva; María Luisa Fernández-Soto; Jordi Salas-Salvadó; María D Ballesteros-Pomar; Andreea Ciudin; Ferran Torres; Concepción Vidal; María José Morales; Sergio Valdés; Silvia Pellitero; Inka Miñambres; Lluís Masmiquel; Albert Goday; Lorena Suarez; Liliam Flores; Marta Bueno; Assumpta Caixàs; Irene Bretón; Rosa Cámara; Romina Olbeyra; Rona Penso; María José de la Cruz; Andreu Simó-Servat; Francisca María Pereyra-García; Elena Teresa López-Mezquita; Anna Gils; Enzamaria Fidilio; Orosia Bandrés; Ángel Martínez; Jose Abuín; Montserrat Marques-Pamies; Laura Tuneu; Magdalena Arteaga; Olga Castañer; Fernando Goñi; Cristina Arrizabalaga; Manuel Antonio Botana; Alfonso Calañas; Ángel Rebollo Journal: J Clin Med Date: 2020-04-09 Impact factor: 4.241
Authors: William P Martin; James White; Francisco J López-Hernández; Neil G Docherty; Carel W le Roux Journal: Front Endocrinol (Lausanne) Date: 2020-08-17 Impact factor: 5.555